Protalix boosted by late-stage Gaucher success

Protalix was buoyed by the news that its late-stage trial for its Gaucher disease drug met its primary endpoint. Researchers reported that patients taking Uplyso demonstrated a significantly smaller spleen volume. Patients with the rare enzyme disorder also had smaller livers and higher hemoglobin levels after taking the drug. As Reuters notes, Protalix's success adds more pressure on Genzyme, which makes the blockbuster Cerezyme for Gaucher disease. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.